Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 1/20 | 0.39 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.39 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.36 |
| ▸ | PDE8B | O95263 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30314505 | 1.00 | CHRM2 (0.39) | CHRM2CHRM1CHRM3HSD17B10NR1H2 | |
| SCHEMBL23895462 | 0.87 | CHRM2 (0.40) | CHRM2CHRM1CHRM3HSD17B10NR1H2 | |
| SCHEMBL291076 | 0.87 | NR1H2 (0.43) | CHRM2CHRM1CHRM3HSD17B10NR1H2 | |
| SCHEMBL3421417 | 0.87 | NR1H2 (0.43) | CHRM2CHRM1CHRM3HSD17B10NR1H2 | |
| SCHEMBL1630475 | 0.86 | HTT (0.43) | CHRM2CHRM1CHRM3HSD17B10PDE8B | |
| SCHEMBL1398690 | 0.86 | HTT (0.43) | CHRM2CHRM1CHRM3HSD17B10PDE8B | |
| SCHEMBL1630474 | 0.86 | HTT (0.43) | CHRM2CHRM1CHRM3HSD17B10PDE8B | |
| SCHEMBL10215607 | 0.85 | CHRM2 (0.39) | CHRM2CHRM1CHRM3HSD17B10NR1H2 | |
| SCHEMBL5504108 | 0.85 | CHRM2 (0.45) | CHRM2CHRM1CHRM3HSD17B10NR1H2 | |
| SCHEMBL29345090 | 0.85 | NR1H2 (0.41) | CHRM2CHRM1CHRM3NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133908-B2 | Heteroaryl derivatives of N-{[(1S,4S,6S)-3-(2-pyridinylcarbonyl)-3-azabicyclo[4.1.0]hept-4-yl]methyl}-2-amine | GLAXO GROUP LIMITED (GB) | 2012-03-13 | — | — | US | disclosed |
| US-20100168131-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168131-A1 | NOVEL COMPOUNDS | HTR3B, HNMT, TPMT | CHRM2 225/4885CHRM1 209/4885CHRM3 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.